Eli Lilly is one of the most prominent drugmakers on the globe. However, with a market cap exceeding $62 billion and product offerings in a wide range of therapeutic areas, it can be difficult for investors to understand every aspect of its business. In this segment, health care analyst Max Macaluso takes a close look at a specific division that generated more than $2 billion in revenue last year but that many Lilly investors might not know about: animal health.
Can Eli Lilly beat the patent cliff?
Over the next two years, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.
The article 1 Eli Lilly Division That Roared Into 2013 originally appeared on Fool.com.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.